OVERVIEW

Disease Risks Treatment and Control - Blood Pressure Management is organized by Southern Medical Association (SMA) and will be held from Jan 04, 2019 - Jan 04, 2020.

Target Audience:
This activity is designed for healthcare professionals including physicians, physician assistants, nurse practitioners, and allied healthcare professionals who manage and treat patients with cardiovascular disease.

Credits Available:
Southern Medical Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All healthcare professionals who are not MDs or DOs will receive a certificate of participation.

Blood Pressure Treatment Guidelines for the Southern Patient:
Hypertension is the world's leading risk factor for cardiovascular and stroke mortality. The American College of Cardiology/American Heart Association (ACC/AHA) this year published the first comprehensive hypertension clinical practice guideline since the 2003 Joint National Committee guideline (JNC-7). This session will review the principle recommendations of the ACC/AHA guideline and the evidence backing up these recommendations. Key new information appearing in the literature subsequent to guideline publication will also be reviewed. At the conclusion of the session, learners should be better prepared to:

• Recognize the latest clinical practice guideline recommendations for high blood pressure in adults;
• Discuss the background evidence supporting these guideline recommendations;
• Identify the latest comparative guideline modeling study results.

CKD progression after stage 3/4:
Once Proteinuric CKD reaches stages 3-4 CKD progresses to End Stage Renal Disease despite tight control of HTN. CKD patients have high CVD mortality. Current clinical approaches have a slight mortality benefit but fail to arrest CKD progression. CKD patients desperately need a treatment (currently unavailable) that targets new pathways that will stop or even reverse disease progression. Strategic possibilities for the development of new approaches/treatments based on novel pathophysiological mechanisms will be discussed. At the conclusion of the session, learners should be able to identify:

• Chronic Kidney Disease (CKD)affects 26 million Americans and is a growing public
• Chronic Kidney Disease (CKD)affects 26 million Americans and is a growing public health concern; it is disproportionately elevated in minority populations and those of lower economic status.
• CKD significantly increases the risk of premature death and cardiovascular disease (CVD). CVD is the leading cause of death in all stages of CKD.
• The prevalence of Stage 3 CKD (GFR 45-60) is ~ 30 times greater than the prevalence of End-Stage Kidney Disease (ESKD). Most CKD patients do not proceed to ESRD but die before the onset of ESRD.

Diabetes Treatment:
The goal of this activity is to review the clinical trial evidence supporting systolic and diastolic blood pressure goals in patients with hypertension and diabetes, and the recent guidelines recommend for blood pressure treatment in patients with diabetes. The benefits of various classes of antihypertensive agents demonstrated in clinical trials and what recent guidelines recommend for selection of various antihypertensive classes in diabetes will also be reviewed. At the conclusion of the session, learners should be better prepared to:

• Describe the evidence from clinical trials supporting blood pressure goals in hypertensive patients with diabetes.
• Discuss recommendations for systolic and diastolic blood pressure goals in patients with diabetes in recent hypertension guidelines.
• Describe the evidence supporting selection of various classes of antihypertensive agents in diabetes.
• Discuss the recommendations for selection of different classes of antihypertensive agents in diabetes.

Additional details will be posted as soon as they are available.